Bicalutamide + Placebo
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-metastatic Prostate Cancer
Conditions
Non-metastatic Prostate Cancer
Trial Timeline
Aug 1, 1995 → Aug 1, 2008
NCT ID
NCT00657904About Bicalutamide + Placebo
Bicalutamide + Placebo is a phase 3 stage product being developed by AstraZeneca for Non-metastatic Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00657904. Target conditions include Non-metastatic Prostate Cancer.
What happened to similar drugs?
1 of 5 similar drugs in Non-metastatic Prostate Cancer were approved
Approved (1) Terminated (0) Active (4)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00672282 | Phase 3 | Completed |
| NCT00673205 | Phase 3 | Completed |
| NCT00657904 | Phase 3 | Completed |
Competing Products
14 competing products in Non-metastatic Prostate Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Bicalutamide + Placebo | AstraZeneca | Phase 3 | 40 |
| Gefitinib, radiotherapy | AstraZeneca | Phase 1/2 | 32 |
| Gefitinib, 5-fluorouracil, leucovorin and radiotherapy | AstraZeneca | Phase 1/2 | 24 |
| Bicalutamide + Placebo | AstraZeneca | Phase 3 | 40 |
| Avelumab | Merck | Phase 2 | 35 |
| Doxorubicin + Ifosfamide or dacarbazine + Doxorubicin + Ifosfamide or dacarbazine + At the discretion of the investigator | Novartis | Phase 3 | 47 |
| HSP-130 | Pfizer | Phase 2 | 35 |
| AK104 + Lenvatinib | Akeso | Phase 2 | 39 |
| Darolutamide (Nubeqa, BAY1841788) | Bayer | Pre-clinical | 30 |
| Darolutamide (Nubeqa, BAY1841788) + Enzalutamide + Apalutamide | Bayer | Pre-clinical | 23 |
| Darolutamide (Nubeqa, BAY1841788) + Enzalutamide + Apalutamide | Bayer | Pre-clinical | 23 |
| Darolutamide (Nubeqa, BAY1841788) + Placebo | Bayer | Phase 3 | 37 |
| Darolutamide (Nubeqa, BAY1841788) | Bayer | Approved | 47 |
| Apalutamide + Darolutamide (BAY 1841788) + Enzalutamide | Bayer | Pre-clinical | 23 |